Skip to main content

Neuromuscular-Junction-on-a-Chip to study medication for Parkinson

Project description

Innovative chip-based device for the screening of Parkinson's disease medications

There is a growing interest in developing and investing in organ-on-a-chip devices from basic researchers and biotech and pharmaceutical companies. The lab-on-a-chip devices offer highly accessible systems for testing hypothesis-driven research ideas and screening of potential therapeutic compounds. Importantly, chip-based devices allow ultra-low-cost test solutions for medications. The goal of the EU-funded NMJ project is to develop a neuromuscular-junction-on-a-chip device tailored as α-synuclein-induced Parkinson's disease model. The objective is to introduce this chip-based device for testing Parkinson's disease medications proposed by Novartis and GlaxoSmithKline. The French microfluidic innovation centre Elvesys in Paris will provide expert support to the project.


Net EU contribution
€ 184 707,84
172 Rue De Charonne B2 2 Eme Etage
75011 Paris

See on map

Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00